Rodger MD - Crispr Therapeutics Chairman Founder
| CRSP Stock | USD 53.74 0.32 0.59% |
Insider
Rodger MD is Chairman Founder of Crispr Therapeutics AG
| Age | 57 |
| Address | Baarerstrasse 14, Zug, Switzerland, 6300 |
| Phone | 41 41 561 32 77 |
| Web | https://www.crisprtx.com |
Crispr Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0797) % which means that it has lost $0.0797 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1102) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/01/2024, Return On Tangible Assets is likely to drop to -0.07. In addition to that, Return On Capital Employed is likely to grow to -0.1. As of 06/01/2024, Total Current Liabilities is likely to drop to about 63.5 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 1.3 BSimilar Executives
| Showing other executives | INSIDER Age | ||
| Yvonne MBA | NkartaInc | 64 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Stephanie Yao | Kronos BioInc | N/A | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Brian Sullivan | Elevation Oncology | N/A | |
| BCh BM | Kronos BioInc | 40 | |
| James Trager | NkartaInc | 61 | |
| Noreen MD | Kezar Life Sciences | 59 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Marni Kottle | Kronos BioInc | N/A | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Ralph Brandenberger | NkartaInc | 55 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Valerie MD | Elevation Oncology | 46 | |
| Joshua Kazam | Kronos BioInc | 47 | |
| Nadir Mahmood | NkartaInc | 45 | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0797 |
Crispr Therapeutics Leadership Team
Elected by the shareholders, the Crispr Therapeutics' board of directors comprises two types of representatives: Crispr Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crispr. The board's role is to monitor Crispr Therapeutics' management team and ensure that shareholders' interests are well served. Crispr Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crispr Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samarth Kulkarni, Chief Business Officer | ||
| Susan Kim, Vice Relations | ||
| Craig Mello, Scientific Member | ||
| Lawrence Klein, Chief Officer | ||
| Chad Cowan, Scientific Founder | ||
| Rodger MD, Chairman Founder | ||
| Daniel Anderson, Scientific Member | ||
| Emmanuelle Charpentier, CoFounder Member | ||
| Raju Prasad, Chief Officer | ||
| Matthew MD, Scientific Member | ||
| Stephen Kennedy, Head Operations | ||
| James Kasinger, General Counsel, Secretary to the Board of Directors | ||
| Brendan MBA, CFO VP | ||
| MD FACP, Chief Officer | ||
| Shaun Foy, Founder |
Crispr Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crispr Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0797 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (278.94) % | ||||
| Current Valuation | 2.72 B | ||||
| Shares Outstanding | 84.92 M | ||||
| Shares Owned By Insiders | 1.86 % | ||||
| Shares Owned By Institutions | 71.19 % | ||||
| Number Of Shares Shorted | 15.33 M | ||||
| Price To Earning | 17.33 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.70) | Revenue Per Share 3.396 | Quarterly Revenue Growth (0.99) | Return On Assets (0.08) | Return On Equity (0.11) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.